Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec 6:9:2459.
doi: 10.3389/fpsyg.2018.02459. eCollection 2018.

Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study

Affiliations

Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study

Joseph Barsuglia et al. Front Psychol. .

Abstract

5-MeO-DMT is a psychoactive substance found in high concentrations in the bufotoxin of the Colorado River Toad (Bufo alvarius). Emerging evidence suggests that vaporized 5-MeO-DMT may occasion mystical experiences of comparable intensity to those occasioned by more widely studied psychedelics such as psilocybin, but no empirical study has tested this hypothesis. Data was obtained from 20 individuals (M age = 38.9, ± 10.7; male = 55%, Caucasian = 85%) who were administered 5-MeO-DMT as part of a psychospiritual retreat program in Mexico. All participants received 50 mg of inhaled vaporized toad bufotoxin which contains 5-MeO-DMT and completed the Mystical Experience Questionnaire (MEQ30) approximately 4-6 h after their session. Administration of 5-MeO-DMT occasioned strong mystical experiences (MEQ30 Overall M intensity = 4.17, ± 0.64, range 0-5) and the majority (n = 15, 75%) had "a complete mystical experience" (≥60% on all MEQ30 subscales). Compared to a prior laboratory-based psilocybin study, there were no differences in the intensity of mystical effects between 5-MeO-DMT and a high dose (30 mg/70 kg) of psilocybin, but the intensity of mystical effects was significantly higher in the 5-MeO-DMT sample compared to moderate/high dose (20 mg/70 kg) of psilocybin (MEQ30 Total Score: p = 0.02, d = 0.81). Administration of vaporized 5-MeO-DMT reliably occasioned complete mystical experiences in 75% of individuals and was similar in intensity to high dose psilocybin administered in a laboratory setting. The short duration of action may be advantageous for clinical interventions and for studying mystical-type experiences.

Keywords: 5-MeO-DMT; Bufo alvarius; Colorado river toad; DMT; mystical experience; psychedelic; tryptamines.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Comparison of psilocybin and 5-MeO-DMT groups on the Mystical Experiences Questionnaire (MEQ30). 5-MeO-DMT results from current study and psilocybin ratings from the Griffiths et al., 2011 dose-related effects study. No significant differences are observed between the 5-MeO-DMT and 30 mg/70 kg Psilocybin group. Significant differences are observed between the 5-MeO-DMT and 20 mg/70 kg group. p < 0.05, ∗∗p < 0.01. The 10 mg/70 kg, 5 mg/70 kg, and 0 mg placebo groups from Griffiths et al. (2011) are plotted for visual reference and were not statistically compared.

References

    1. Barrett F. S., Johnson M. W., Griffiths R. R. (2015). Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin. J. Psychopharmacol. 29 1182–1190. 10.1177/0269881115609019 - DOI - PMC - PubMed
    1. Bogenschutz M. P., Forcehimes A. A., Pommy J. A., Wilcox C. E., Barbosa P. C. R., Strassman R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J. Psychopharmacol. 29 289–299. 10.1177/0269881114565144 - DOI - PubMed
    1. Cowen P. (2016). Altered states: psilocybin for treatment-resistant depression. Lancet Psychiatry 3 592–593. 10.1016/S2215-0366(16)30087-6 - DOI - PubMed
    1. Davis A. K., Barsuglia J. P., Lancelotta R. L., Grant R., Renn E. (2018). The epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) use: benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J. Psychopharmacol. 32 779–792. 10.1177/0269881118769063 - DOI - PMC - PubMed
    1. Davis A. K., So S., Lancelotta R., Barsuglia J. P., Griffiths R. R. (in press). 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) used in a naturalistic setting is associated with subjective improvements in depression and anxiety. J. Psychopharmacol. - PMC - PubMed